Annabel Rigou1, Joëlle Le Moal2, Juliane Léger3,4, Alain Le Tertre2, Jean-Claude Carel3,4. 1. Environmental Health Division, Santé publique France, 12 rue duVal d'Osne, 94415, Saint-Maurice, France. annabel.rigou@santepubliquefrance.fr. 2. Environmental Health Division, Santé publique France, 12 rue duVal d'Osne, 94415, Saint-Maurice, France. 3. Department of Pediatric Endocrinology and Diabetology, and Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Robert-Debré, F-75019, Paris, France. 4. PROTECT, INSERM, Université Paris Diderot, Sorbonne Paris Cité, F-75019, Paris, France.
Abstract
Clinical precocious puberty (PP) is a disease, reputed to be on the increase and suspected to be linked to endocrine disrupting chemicals (EDC) exposure. Population-based epidemiological data are lacking in France and scarce elsewhere. We accessed the feasibility of monitoring PP nationwide in France in this context, using a nationwide existing database, the French National Health Insurance Information System. Here, we present the method we used with a step-by-step approach to build and select the most suitable indicator. We built three indicators reflecting the incidence of idiopathic central precocious puberty (ICPP), the most frequent form of PP, and we compared these indicators according to their strengths and weaknesses with respect to surveillance purposes. CONCLUSION: Monitoring ICPP in France proved feasible using a Drug reimbursement indicator. Our method is cost efficient and highly relevant in public health surveillance. Our step-by-step approach proved helpful to achieve this project and could be proposed for assessing the feasibility of monitoring health outcomes of interest using existing data bases. What is known: • Precocious puberty (PP) is suspected to be related to EDC exposure and it is believed to be on the increase in France and in others countries. • Very few epidemiologic data on PP are currently available in the world at the national scale. What is new: • This is the first study describing a method to monitor the most frequent form of PP, idiopathic central PP (ICPP) nationwide in a cost-efficient way, using health insurance databases. • This cost-effective method will allow to estimate and monitor the incidence of ICPP in France and to analyze spatial variations at a very precise scale, which will be very useful to examine the role of environmental exposures, especially to EDCs.
Clinical precocious puberty (PP) is a disease, reputed to be on the increase and suspected to be linked to endocrine disrupting chemicals (EDC) exposure. Population-based epidemiological data are lacking in France and scarce elsewhere. We accessed the feasibility of monitoring PP nationwide in France in this context, using a nationwide existing database, the French National Health Insurance Information System. Here, we present the method we used with a step-by-step approach to build and select the most suitable indicator. We built three indicators reflecting the incidence of idiopathic central precocious puberty (ICPP), the most frequent form of PP, and we compared these indicators according to their strengths and weaknesses with respect to surveillance purposes. CONCLUSION: Monitoring ICPP in France proved feasible using a Drug reimbursement indicator. Our method is cost efficient and highly relevant in public health surveillance. Our step-by-step approach proved helpful to achieve this project and could be proposed for assessing the feasibility of monitoring health outcomes of interest using existing data bases. What is known: • Precocious puberty (PP) is suspected to be related to EDC exposure and it is believed to be on the increase in France and in others countries. • Very few epidemiologic data on PP are currently available in the world at the national scale. What is new: • This is the first study describing a method to monitor the most frequent form of PP, idiopathic central PP (ICPP) nationwide in a cost-efficient way, using health insurance databases. • This cost-effective method will allow to estimate and monitor the incidence of ICPP in France and to analyze spatial variations at a very precise scale, which will be very useful to examine the role of environmental exposures, especially to EDCs.
Authors: M Cisternino; T Arrigo; A M Pasquino; C Tinelli; F Antoniazzi; L Beduschi; G Bindi; P Borrelli; V De Sanctis; G Farello; F Galluzzi; L Gargantini; D Lo Presti; M Sposito; L Tatò Journal: J Pediatr Endocrinol Metab Date: 2000-07 Impact factor: 1.634
Authors: Germaine M Buck Louis; L Earl Gray; Michele Marcus; Sergio R Ojeda; Ora H Pescovitz; Selma Feldman Witchel; Wolfgang Sippell; David H Abbott; Ana Soto; Rochelle W Tyl; Jean-Pierre Bourguignon; Niels E Skakkebaek; Shanna H Swan; Mari S Golub; Martin Wabitsch; Jorma Toppari; Susan Y Euling Journal: Pediatrics Date: 2008-02 Impact factor: 7.124
Authors: Jean-Claude Carel; Erica A Eugster; Alan Rogol; Lucia Ghizzoni; Mark R Palmert; Franco Antoniazzi; Sheri Berenbaum; Jean-Pierre Bourguignon; George P Chrousos; Joël Coste; Sheri Deal; Liat de Vries; Carol Foster; Sabine Heger; Jack Holland; Kirsi Jahnukainen; Anders Juul; Paul Kaplowitz; Najiba Lahlou; Mary M Lee; Peter Lee; Deborah P Merke; E Kirk Neely; Wilma Oostdijk; Moshe Phillip; Robert L Rosenfield; Dorothy Shulman; Dennis Styne; Maïthé Tauber; Jan M Wit Journal: Pediatrics Date: 2009-03-30 Impact factor: 7.124
Authors: Joëlle Le Moal; Richard M Sharpe; Niels Jϕrgensen; Hagai Levine; Joanna Jurewicz; Jaime Mendiola; Shanna H Swan; Helena Virtanen; Sophie Christin-Maître; Sylvaine Cordier; Jorma Toppari; Wojciech Hanke Journal: Eur J Public Health Date: 2015-09-01 Impact factor: 3.367